Keybanc Maintains Overweight on Exagen, Raises Price Target to $15
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.